Tardive Dyskinesia

Updated: May 15, 2023

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

deutetrabenazine

When not switching from tetrabenazine, the initial dose is 6 mg orally twice a day. 12 mg orally daily as an extended-release tablet; The dose can be increased in the weekly increments of about 6 mg daily depending on the tolerability and response, should not exceed more than 48 mg daily.

Dose Adjustments

Dosage Modifications
CYP2D6 inhibitors (Strong)
daily dose of deutetrabenazine: should not exceed more than 36 mg daily (maximum single dose of 18 mg)
Examples of quinidine and antidepressants with strong CYP2D6 inhibitors (eg,fluoxetine, paroxetine, bupropion)
CYP2D6 metabolizers (Poor)
daily dose of deutetrabenazine: should not exceed more than 36 mg daily (maximum single dose of 18 mg)
Hepatic impairment
Contraindicated